Literature DB >> 25701268

Occurrence of Malignant Tumours in the Acute Hepatic Porphyrias.

Estefanía Lang1, Martin Schäfer, Holger Schwender, Norbert J Neumann, Jorge Frank.   

Abstract

The porphyrias are a group of inherited metabolic diseases resulting from enzymatic deficiencies of specific haem biosynthetic enzymes. They can be classified as primarily acute and non-acute types. Clinically, the acute hepatic porphyrias (AHPs) are characterised by acute neurovisceral attacks. Patients with AHP may be at increased risk for development of hepatocellular carcinoma (HCC). However, systematic studies on the occurrence of other malignancies in patients with the AHPs have not been performed to date. Here, we studied the development of HCC and distinct malignant tumours in patients with the AHPs registered in a single European porphyria specialist centre. A questionnaire was designed and sent to all individuals (n = 122) diagnosed between 1970 and 2012 of whom a valid address was available (n = 82), requesting information on their personal and family history of cancer. Statistical analysis was performed to calculate incidence, prevalence and relative risk of HCC. To calculate confidence intervals, a Poisson distribution was assumed. Forty-nine patients (59.8%) returned a completed questionnaire. Overall, HCC was diagnosed in one female (2.1%), and the remaining patients reported on six distinct malignancies. We were able to confirm that HCC is an important complication in AHP. The patients in our cohort had an approximately 35-fold increased risk of developing HCC, similar to observations in other European countries. In addition, we detected colon, breast, uterine and thyroid cancer as well as lymphoma and a liver metastasis in patients with AHP. However, considering the small number of tumours and patients studied here, the data should be interpreted with caution, and further studies on cancer occurrence in AHP patients will require a multicentre setting.

Entities:  

Year:  2015        PMID: 25701268      PMCID: PMC4486276          DOI: 10.1007/8904_2015_406

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  29 in total

1.  Treatment and treatment considerations in a patient with advanced breast cancer and acute intermittent porphyria.

Authors:  Charlotte Kristiansen; Sven Tyge Langkjer
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

2.  A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)

Authors:  K Ulm
Journal:  Am J Epidemiol       Date:  1990-02       Impact factor: 4.897

Review 3.  The changing pattern of epidemiology in hepatocellular carcinoma.

Authors:  Helena Nordenstedt; Donna L White; Hashem B El-Serag
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

4.  Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden.

Authors:  E Innala; C Andersson
Journal:  J Intern Med       Date:  2010-12-28       Impact factor: 8.989

5.  Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors.

Authors:  C Andant; H Puy; C Bogard; J Faivre; J C Soulé; Y Nordmann; J C Deybach
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

Review 6.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 7.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

8.  High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria.

Authors:  Eliane Sardh; Staffan Wahlin; Mikael Björnstedt; Pauline Harper; Dan E H Andersson
Journal:  J Inherit Metab Dis       Date:  2013-01-23       Impact factor: 4.982

9.  Porphyrias, porphyrins and hepatocellular cancer.

Authors:  N O Bengtsson; L Hardell
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

10.  Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria--an epidemiological investigation.

Authors:  L Hardell; N O Bengtsson; U Jonsson; S Eriksson; L G Larsson
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

View more
  6 in total

Review 1.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

2.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Authors:  Oxana V Makarova-Rusher; Sean F Altekruse; Tim S McNeel; Susanna Ulahannan; Austin G Duffy; Barry I Graubard; Tim F Greten; Katherine A McGlynn
Journal:  Cancer       Date:  2016-03-21       Impact factor: 6.860

Review 3.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

Review 4.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 5.  Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review.

Authors:  Daryl Ramai; Smit S Deliwala; Saurabh Chandan; Janice Lester; Jameel Singh; Jayanta Samanta; Sara di Nunzio; Fabio Perversi; Francesca Cappellini; Aashni Shah; Michele Ghidini; Rodolfo Sacco; Antonio Facciorusso; Luca Giacomelli
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

6.  Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.

Authors:  Mattias Lissing; Daphne Vassiliou; Ylva Floderus; Pauline Harper; Matteo Bottai; Marianna Kotopouli; Hannes Hagström; Eliane Sardh; Staffan Wahlin
Journal:  J Intern Med       Date:  2022-03-02       Impact factor: 13.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.